<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">8GtywngFkMYzN4XXhyGRT7r</article-id>
      <article-id pub-id-type="other">00010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001600010</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500610</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000125</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rela&#231;&#227;o entre depress&#227;o, n&#237;vel de BNP e comprometimento ventricular na insufici&#234;ncia card&#237;aca</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Aguiar</surname>
            <given-names>Vera Barretto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ochiai</surname>
            <given-names>Marcelo Eidi</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cardoso</surname>
            <given-names>Juliano Novais</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Del Carlo</surname>
            <given-names>Carlos H</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Morgado</surname>
            <given-names>Paulo Cesar</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Munhoz</surname>
            <given-names>Robinson Tadeu</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pereira-Barretto</surname>
            <given-names>Antonio Carlos</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">S&#227;o Paulo</named-content>
          <named-content content-type="state">S&#227;o Paulo</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">FM </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
        <country country="BR">Brazil</country>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>12</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>6</issue>
      <fpage>732</fpage>
      <lpage>737</lpage>
      <history>
        <date date-type="rev-recd">
          <day>09</day>
          <month>04</month>
          <year>2010</year>
        </date>
        <date date-type="received">
          <day>26</day>
          <month>10</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>24</day>
          <month>05</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A depress&#227;o &#233; uma comorbidade frequente na insufici&#234;ncia card&#237;aca (IC), mas os mecanismos relacionados a pior evolu&#231;&#227;o de pacientes deprimidos com IC ainda n&#227;o est&#227;o esclarecidos. OBJETIVO: Avaliar o papel da depress&#227;o grave na evolu&#231;&#227;o dos pacientes com IC descompensada. M&#201;TODOS: Estudamos consecutivamente 43 pacientes com IC avan&#231;ada e FE &lt; 40,0%, hospitalizados para compensa&#231;&#227;o card&#237;aca. Os pacientes, ap&#243;s hist&#243;ria e exame f&#237;sico, foram submetidos a exames laboratoriais, incluindo a dosagem de BNP. Ap&#243;s o diagn&#243;stico de depress&#227;o, aplicou-se a escala de Hamilton-D. Depress&#227;o grave foi definida por escore igual ou maior que 18. As vari&#225;veis cl&#237;nico-laboratoriais, segundo a presen&#231;a ou n&#227;o de depress&#227;o grave, foram analisadas pela regress&#227;o log&#237;stica. A curva ROC definiu o ponto de corte para o BNP. RESULTADOS: Depress&#227;o grave ou muito grave foi identificada em 24 (55,8%) pacientes. Os pacientes deprimidos graves n&#227;o diferiram dos n&#227;o deprimidos quanto &#224; idade, sexo e fun&#231;&#227;o renal, mas apresentaram menor comprometimento card&#237;aco (FE 23,4 &#177; 7,2% vs 19,5 &#177; 5,2%; p = 0,046) e valores mais elevados do BNP (2.582,8 &#177; 1.596,6 pg/ml vs 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001). Entretanto, os pacientes com BNP maior que 1.100 pg/ml tiveram 12,0 (odds ratio [IC 95%] = 2,61 - 55,26) vezes mais chance de desenvolverem quadros de depress&#227;o grave. CONCLUS&#195;O: Os pacientes com depress&#227;o grave apresentaram maior grau de estimula&#231;&#227;o neuro-hormonal, apesar do grau de disfun&#231;&#227;o ventricular ser menor. As altera&#231;&#245;es fisiopatol&#243;gicas relacionadas &#224; depress&#227;o, aumentando a estimula&#231;&#227;o neuro-hormonal e as citocinas, provavelmente contribu&#237;ram para essa maior manifesta&#231;&#227;o cl&#237;nica, mesmo em presen&#231;a de menor dano card&#237;aco.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Depress&#227;o</kwd>
        <kwd>comorbidade</kwd>
        <kwd>insufici&#234;ncia card&#237;aca</kwd>
        <kwd>pept&#237;deos natriur&#233;ticos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>17</day>
        <month>09</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>ARTIGO ORIGINAL</bold>
    </p>
    <p>
      <bold>Rela&#231;&#227;o entre depress&#227;o, n&#237;vel de BNP e comprometimento ventricular na insufici&#234;ncia card&#237;aca</bold>
    </p>
    <p>
      <bold>Vera Barretto Aguiar; Marcelo Eidi Ochiai; Juliano Novais Cardoso; Carlos H Del Carlo; Paulo Cesar Morgado; Robinson Tadeu Munhoz; Antonio Carlos Pereira-Barretto</bold>
    </p>
    <p>Hospital Auxiliar de Cotox&#243; - Instituto do Cora&#231;&#227;o - HC FMUSP, S&#227;o Paulo, SP - Brasil</p>
    <p>
      <xref ref-type="corresp" rid="back">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO: </bold> A depress&#227;o &#233; uma comorbidade frequente na insufici&#234;ncia card&#237;aca (IC), mas os mecanismos relacionados a pior evolu&#231;&#227;o de pacientes deprimidos com IC ainda n&#227;o est&#227;o esclarecidos. </p>
    <p><bold>OBJETIVO: </bold> Avaliar o papel da depress&#227;o grave na evolu&#231;&#227;o dos pacientes com IC descompensada. </p>
    <p><bold>M&#201;TODOS:</bold> Estudamos consecutivamente 43 pacientes com IC avan&#231;ada e FE &lt; 40,0%, hospitalizados para compensa&#231;&#227;o card&#237;aca. Os pacientes, ap&#243;s hist&#243;ria e exame f&#237;sico, foram submetidos a exames laboratoriais, incluindo a dosagem de BNP. Ap&#243;s o diagn&#243;stico de depress&#227;o, aplicou-se a escala de Hamilton-D. Depress&#227;o grave foi definida por escore igual ou maior que 18. As vari&#225;veis cl&#237;nico-laboratoriais, segundo a presen&#231;a ou n&#227;o de depress&#227;o grave, foram analisadas pela regress&#227;o log&#237;stica. A curva ROC definiu o ponto de corte para o BNP. </p>
    <p><bold>RESULTADOS: </bold> Depress&#227;o grave ou muito grave foi identificada em 24 (55,8%) pacientes. Os pacientes deprimidos graves n&#227;o diferiram dos n&#227;o deprimidos quanto &#224; idade, sexo e fun&#231;&#227;o renal, mas apresentaram menor comprometimento card&#237;aco (FE 23,4 &#177; 7,2% <italic>vs</italic> 19,5 &#177; 5,2%; p = 0,046) e valores mais elevados do BNP (2.582,8 &#177; 1.596,6 pg/ml <italic>vs</italic> 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001). Entretanto, os pacientes com BNP maior que 1.100 pg/ml tiveram 12,0 (<italic>odds ratio</italic> [IC 95%] = 2,61 - 55,26) vezes mais chance de desenvolverem quadros de depress&#227;o grave. </p>
    <p><bold>CONCLUS&#195;O: </bold> Os pacientes com depress&#227;o grave apresentaram maior grau de estimula&#231;&#227;o neuro-hormonal, apesar do grau de disfun&#231;&#227;o ventricular ser menor. As altera&#231;&#245;es fisiopatol&#243;gicas relacionadas &#224; depress&#227;o, aumentando a estimula&#231;&#227;o neuro-hormonal e as citocinas, provavelmente contribu&#237;ram para essa maior manifesta&#231;&#227;o cl&#237;nica, mesmo em presen&#231;a de menor dano card&#237;aco.</p>
    <p><bold>Palavras-chave: </bold> Depress&#227;o, comorbidade, insufici&#234;ncia card&#237;aca, pept&#237;deos natriur&#233;ticos/an&#225;lise.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A insufici&#234;ncia card&#237;aca (IC) &#233; reconhecida como uma s&#237;ndrome que cursa com alta morbidade e mortalidade<sup>1-3</sup>. Tanto a morbidade como a mortalidade sofrem a influ&#234;ncia das comorbidades que os pacientes apresentam e pacientes com comorbidades, entre elas a depress&#227;o, evoluem pior<sup>1,3</sup>.</p>
    <p>Na popula&#231;&#227;o em geral, de 5,0% a 10,0% dos indiv&#237;duos apresentam crit&#233;rios para o diagn&#243;stico de depress&#227;o. Em portadores de insufici&#234;ncia card&#237;aca atendidos em ambulat&#243;rios, essa preval&#234;ncia fica entre 11,0% a 25,0%, e em pacientes com IC hospitalizados, aumenta para a faixa de 35,0% a 70,0%<sup>4</sup>. A ampla varia&#231;&#227;o na incid&#234;ncia decorre das diferentes t&#233;cnicas empregadas para o diagn&#243;stico, bem como das caracter&#237;sticas das popula&#231;&#245;es estudadas, considerando-se a idade, sexo e a intensidade da IC<sup>5</sup>. De qualquer maneira, observa-se uma forte associa&#231;&#227;o entre a IC e depress&#227;o<sup>6-13</sup>.</p>
    <p>A IC e a depress&#227;o t&#234;m aspectos fisiopatol&#243;gicos comuns, ambas aumentando a estimula&#231;&#227;o do eixo hipot&#225;lamo - hip&#243;fise adrenal e a atividade simp&#225;tica, bem como aumentando as citocinas inflamat&#243;rias circulantes<sup>14-17</sup>. A depress&#227;o pode contribuir para o desenvolvimento da IC em popula&#231;&#227;o suscept&#237;vel, como tamb&#233;m agravar quadros de IC naqueles com a doen&#231;a j&#225; instalada, sendo um preditor de re-hospitaliza&#231;&#245;es e de mortalidade<sup>6,7,10,11</sup>.</p>
    <p>A alta morbimortalidade pode estar relacionada &#224; a&#231;&#227;o sin&#233;rgica entre a IC e a depress&#227;o na ativa&#231;&#227;o neuro-hormonal, a fatores inflamat&#243;rios e &#224; hipercoagulabilidade<sup>5,14,15</sup>. A depress&#227;o ainda influencia negativamente a evolu&#231;&#227;o da IC por estar associada &#224; n&#227;o ader&#234;ncia dos pacientes &#224;s recomenda&#231;&#245;es m&#233;dicas, em especial &#224; tomada das medica&#231;&#245;es<sup>15-17</sup>. Os pacientes com IC deprimidos s&#227;o mais sintom&#225;ticos, apresentando-se em classe funcional mais elevada e, com frequ&#234;ncia, t&#234;m pior qualidade de vida.</p>
    <p>Frente a estes achados, procuramos verificar o papel da depress&#227;o grave no quadro cl&#237;nico dos pacientes com IC avan&#231;ada internados, em um hospital terci&#225;rio, para compensa&#231;&#227;o card&#237;aca.</p>
    <p>
      <bold>M&#233;todos</bold>
    </p>
    <p>Em um grande hospital terci&#225;rio da cidade de S&#227;o Paulo, realizamos um estudo transversal que incluiu consecutivamente 43 pacientes hospitalizados para compensa&#231;&#227;o de insufici&#234;ncia card&#237;aca, para os quais foi solicitada avalia&#231;&#227;o psiqui&#225;trica pelo cl&#237;nico. A avalia&#231;&#227;o psiqui&#225;trica &#233; realizada a crit&#233;rio do cl&#237;nico do paciente, n&#227;o sendo realiza&#231;&#227;o de rotina para todos os pacientes.</p>
    <p>Na chegada ao hospital, todos os pacientes foram avaliados clinicamente e submetidos &#224; avalia&#231;&#227;o laboratorial, que inclu&#237;a um hemograma, hemat&#243;crito, dosagem s&#233;rica de ureia, creatinina, s&#243;dio, pot&#225;ssio e dosagem do pept&#237;deo natriur&#233;tico do tipo B (BNP).</p>
    <p>Foram inclu&#237;dos no estudo pacientes com fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo &lt; 0,40, para os quais foi solicitada avalia&#231;&#227;o psiqui&#225;trica pelo cl&#237;nico. Foram crit&#233;rios de exclus&#227;o: <italic>delirium</italic>, dem&#234;ncia, psicose, transtornos afetivos bipolares, sepsis, neoplasias e creatinina basal &gt; 3,0 mg/dl.</p>
    <p>A fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE) foi calculada atrav&#233;s de estudo ecocardiogr&#225;fico, empregando-se o m&#233;todo de Teichholz ou Simpson, realizados pelo menos nos 6 meses pr&#233;vios &#224; interna&#231;&#227;o. A dosagem de BNP foi realizada pelo m&#233;todo imunoensaio por quimioluminesc&#234;ncia, sistema ADVIA Centaur<sup>&#174;</sup> (Roche Inc.), expressa em pg/ml.</p>
    <p>Os pacientes que apresentavam os crit&#233;rios de inclus&#227;o e n&#227;o apresentavam os crit&#233;rios de exclus&#227;o foram submetidos &#224; avalia&#231;&#227;o da depress&#227;o atrav&#233;s da escala de avalia&#231;&#227;o de depress&#227;o de Hamilton - D, vers&#227;o 17 itens. Nessa escala, os pacientes s&#227;o considerados da seguinte forma:</p>
    <disp-quote>
      <p>- de 0 a 7 pontos, normais;</p>
      <p>- de 8 a 13 pontos, portadores de depress&#227;o leve;</p>
      <p>- de 14 a 18 pontos, com depress&#227;o moderada;</p>
      <p>- de 19 a 22 pontos, com depress&#227;o grave; e</p>
      <p>- 23 ou mais pontos, com depress&#227;o muito grave.</p>
    </disp-quote>
    <p>De acordo com o resultado da avalia&#231;&#227;o da presen&#231;a de depress&#227;o, os pacientes foram divididos em dois grupos: grupo 1 - constitu&#237;do pelos pacientes com menos de 18 na escala do teste de Hamilton (eut&#237;micos ou depress&#227;o leve e moderada) e grupo 2 - constitu&#237;do pelos pacientes com escore maior de 18 (depress&#227;o grave ou muito grave).</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>As vari&#225;veis categ&#243;ricas foram expressas com propor&#231;&#227;o e porcentagem e as vari&#225;veis cont&#237;nuas foram expressas com m&#233;dia e desvio-padr&#227;o.</p>
    <p>As compara&#231;&#245;es entre as vari&#225;veis cont&#237;nuas foram analisadas pelo teste <italic>t</italic> de <italic>Student</italic>. O teste do qui-quadrado ou o teste Exato de Fisher foram utilizados para avaliar as vari&#225;veis categ&#243;ricas. Construiu-se a curva <italic>ROC</italic> para an&#225;lise do melhor ponto de corte entre os n&#237;veis de BNP e a avalia&#231;&#227;o da intensidade da depress&#227;o. A an&#225;lise de regress&#227;o log&#237;stica univariada e m&#250;ltipla foi utilizada para determina&#231;&#227;o dos preditores de depress&#227;o. As vari&#225;veis com p &lt; 0,200 na an&#225;lise univariada foram inclu&#237;das na an&#225;lise multivariada. O modelo final foi constru&#237;do com o procedimento <italic>stepwise forward</italic>. No modelo final, permaneceram as vari&#225;veis com p &lt; 0,05.</p>
    <p>Nas compara&#231;&#245;es, as diferen&#231;as com valor de p &lt; 0,05 foram consideradas como significante.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>Na <xref ref-type="table" rid="t1">Tabela 1</xref>, apresentamos as principais caracter&#237;sticas cl&#237;nicas dos pacientes.</p>
    <table-wrap id="t1">
      <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt01.jpg"/></table-wrap>
    <p>A idade m&#233;dia dos pacientes foi de 54,3 &#177; 15,9 anos.</p>
    <p>Nessa popula&#231;&#227;o, todos se encontravam em classe funcional IV (NYHA), a FEVE m&#233;dia foi de 21,6 &#177; 6,6 e a dosagem de BNP de 1.974 &#177; 1.421,9 pg/ml. Tais achados caracterizam os pacientes como portadores de IC avan&#231;ada.</p>
    <p>Constatou-se tamb&#233;m que a maioria dos pacientes com IC e disfun&#231;&#227;o ventricular sist&#243;lica internados para compensa&#231;&#227;o apresentava quadro de depress&#227;o grave ou muito grave (24 pacientes - 55,8%).</p>
    <p>Na <xref ref-type="table" rid="t2">Tabela 2</xref>, apresentamos os resultados das vari&#225;veis conforme a presen&#231;a ou n&#227;o de depress&#227;o grave ou muito grave.</p>
    <table-wrap id="t2">
      <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt02.jpg"/></table-wrap>
    <p>Os pacientes com depress&#227;o grave ou muito grave n&#227;o diferiram dos sem depress&#227;o ou com depress&#227;o leve e moderada quanto &#224; idade, sexo e fun&#231;&#227;o renal, mas apresentaram menor comprometimento card&#237;aco (FEVE 23,4 &#177; 7,2% <italic>vs</italic> 19,5 &#177; 5,2%; p = 0,046) e valores mais elevados do BNP (2.582,8 &#177; 1.596,6 pg/ml <italic>vs</italic> 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001).</p>
    <p>Frente &#224; diferen&#231;a nos valores de BNP entre os pacientes com depress&#227;o grave ou muito grave e os outros, construiu-se a curva <italic>ROC</italic> que identificou, como o melhor n&#237;vel de corte, o valor de BNP de 1.100 pg/ml (&#193;rea sob a curva = 0,79), com sensibilidade = 87,5% e especificidade = 63,2%.</p>
    <p>Na an&#225;lise de regress&#227;o log&#237;stica, o BNP foi a &#250;nica vari&#225;vel independente relacionada com o aumento de risco de depress&#227;o grave, sendo que os pacientes com BNP <underline>&gt;</underline> 1.100 pg/ml apresentaram chance 12,0 vezes maior de desenvolverem depress&#227;o grave (<xref ref-type="table" rid="t3">Tabela 3</xref>).</p>
    <table-wrap id="t3">
      <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt03.jpg"/></table-wrap>
    <p>Nessa popula&#231;&#227;o estudada, 12/43 (27,9%) pacientes morreram durante a hospitaliza&#231;&#227;o, sendo 3/19 (15,7%) do grupo com depress&#227;o leve a moderada e 9/24 (37,5%) no grupo com depress&#227;o grave ou muito grave (p = 0,115). No seguimento de 90 dias ap&#243;s a interna&#231;&#227;o, ocorreram mais tr&#234;s mortes, uma no grupo com depress&#227;o leve a moderada e duas no grupo com depress&#227;o mais intensa. No total, ao final de 90 dias, 15/43 (34,8%) pacientes faleceram, sendo 4/19 (21,0%) no grupo com depress&#227;o leve e moderada e 11/24 (45,8%) no grupo com depress&#227;o grave ou muito grave (p = 0,090).</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>A IC &#233; uma doen&#231;a que, nas formas avan&#231;adas, evolui com alta morbimortalidade<sup>1-3</sup>. A presen&#231;a de comorbidades pode piorar a evolu&#231;&#227;o dos pacientes, aumentando ainda mais a j&#225; elevada morbimortalidade<sup>3</sup>.</p>
    <p>S&#227;o reconhecidos como fatores associados ao pior progn&#243;stico a presen&#231;a de anemia, de fibrila&#231;&#227;o atrial, disfun&#231;&#227;o tireoidiana, de doen&#231;a pulmonar obstrutiva cr&#244;nica e de depress&#227;o<sup>3</sup>.</p>
    <p>A depress&#227;o &#233; doen&#231;a de muitos aspectos. Havranek e cols<sup>18</sup> identificou 4 fatores independentes relacionados ao desenvolvimento de depress&#227;o: viver sozinho, abuso de &#225;lcool, perda financeira e piora da IC<sup>18</sup>. A perda de suporte social &#233; identificada como um dos mais importantes fatores para a depress&#227;o, aumentando o risco em 3,2 vezes nos homens e 8 vezes nas mulheres<sup>18</sup>.</p>
    <p>A depress&#227;o n&#227;o tem sido analisada sistematicamente nos pacientes com IC, mas, quando pesquisada, constata-se que &#233; relativamente frequente entre eles<sup>6-13</sup>. Em pacientes sem IC, quadros de depress&#227;o maior s&#227;o descritos entre 14,0%-26,0% dos indiv&#237;duos, mas, nos portadores de IC, a incid&#234;ncia aumenta para a faixa de 24,0%-85,0% dos pacientes<sup>4</sup>. A sua preval&#234;ncia aumenta com a idade, mas nitidamente &#233; agravada pela presen&#231;a de IC. A incid&#234;ncia de depress&#227;o n&#227;o s&#243; aumenta com a presen&#231;a de IC como guarda rela&#231;&#227;o com a sua gravidade, sendo tanto mais frequente quanto mais sintom&#225;tica &#233; a IC<sup>11,12,19</sup>. Dessa forma, a frequ&#234;ncia de quadros depressivos &#233; maior nas coortes de pacientes hospitalizados do que entre os pacientes ambulatoriais, provavelmente reflexo da maior gravidade da IC dos pacientes internados<sup>6-13,19</sup>. Constata-se que a depress&#227;o leve pode ser encontrada na maioria dos pacientes hospitalizados por descompensa&#231;&#227;o card&#237;aca, atingindo 85,0% dos pacientes. A depress&#227;o grave &#233; menos frequente<sup>12</sup>.</p>
    <p>A depress&#227;o n&#227;o s&#243; &#233; frequente na IC, como os pacientes com IC e depress&#227;o t&#234;m um risco de morrer de duas a tr&#234;s vezes maior. Os pacientes deprimidos s&#227;o tamb&#233;m hospitalizados em cerca de tr&#234;s vezes mais e a depress&#227;o n&#227;o regride em 1/3 dos pacientes no primeiro ano de seguimento. A depress&#227;o aumenta os custos do tratamento em 25,0%-40,0%, bem como a taxa de hospitaliza&#231;&#227;o, al&#233;m de piorar a classe funcional e prejudicar as atividades di&#225;rias<sup>12</sup>.</p>
    <p>Neste estudo, procuramos avaliar a rela&#231;&#227;o entre a IC e a depress&#227;o em pacientes com IC avan&#231;ada. O diagn&#243;stico de depress&#227;o &#233; realizado atrav&#233;s de uma avalia&#231;&#227;o psiqui&#225;trica e o teste de Hamilton-D auxilia na sua gradua&#231;&#227;o, transformando a avalia&#231;&#227;o em n&#250;meros, o que &#233; &#250;til em pesquisa cient&#237;fica<sup>6,8,10,12,14,15</sup>. Com esse teste, gradua-se a intensidade da depress&#227;o, sendo que, quanto maior o escore, maior a intensidade da doen&#231;a. Neste trabalho, empregamos o teste de Hamilton-D, pela sua acur&#225;cia no diagn&#243;stico da depress&#227;o, pela praticidade em gradu&#225;-la e por ter demonstrado (em v&#225;rios estudos) que avalia o grau de gravidade da depress&#227;o.</p>
    <p>Nossa casu&#237;stica foi composta por pacientes com IC avan&#231;ada. No Hospital Auxiliar de Cotox&#243;, h&#225; um vi&#233;s de gravidade, pois s&#243; s&#227;o internados pacientes que n&#227;o compensaram ou n&#227;o melhoraram com o atendimento no Pronto-Socorro<sup>2</sup>. Nesta popula&#231;&#227;o, 55,8% dos pacientes apresentavam sinais de depress&#227;o grave ou muito grave, identificados por, no teste de Hamilton-D, apresentarem escore superior a 18.</p>
    <p>Quando comparamos nossos dados aos da literatura, constatamos que a incid&#234;ncia de depress&#227;o grave entre nossos pacientes foi mais alta do que a descrita nos estudos publicados com pacientes com IC<sup>8,12,15</sup>. As caracter&#237;sticas de nossa popula&#231;&#227;o, constitu&#237;da por pacientes com IC bastante acentuada, podem ser uma explica&#231;&#227;o para tal achado, em decorr&#234;ncia da forte rela&#231;&#227;o que h&#225; entre a intensidade da IC e a frequ&#234;ncia e intensidade da depress&#227;o. A fisiopatologia, com aspectos comuns entre a IC e a depress&#227;o, pode explicar essa ocorr&#234;ncia, uma vez que tanto a IC quanto a depress&#227;o promovem eleva&#231;&#227;o dos n&#237;veis dos neuro-horm&#244;nios e das citocinas, de tal forma que, atuando juntas, acentuam as altera&#231;&#245;es fisiopatol&#243;gicas que, por sua vez, acentuam as manifesta&#231;&#245;es cl&#237;nicas e a morbimortalidade<sup>13-17,19</sup>.</p>
    <p>Entretanto, foi interessante observar que, em nosso estudo, quando comparamos pacientes com depress&#227;o grave (escore de Hamilton-D &gt; 18) com os sem depress&#227;o ou depress&#227;o leve a moderada, aqueles com depress&#227;o grave ou muito grave apresentavam valores mais elevados de BNP (2.582,8 &#177; 1.596,6 pg/ml <italic>vs</italic> 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001), indicando uma maior intensidade de manifesta&#231;&#245;es de congest&#227;o, em contraste aos valores da fra&#231;&#227;o de eje&#231;&#227;o mais elevados (33,4 &#177; 7,2% <italic>vs</italic> 19,5 &#177; 5,2%; p = 0,046), o que indica menor comprometimento ventricular<sup>12,13,17-19</sup>. Tais dados podem ser considerados como uma documenta&#231;&#227;o da referida sinergia entre a IC e a depress&#227;o na g&#234;nese das manifesta&#231;&#245;es cl&#237;nicas dos pacientes com a doen&#231;a.</p>
    <p>&#201; importante ressaltar que n&#227;o houve diferen&#231;as entre os dois grupos quanto ao sexo, idade, anemia e fun&#231;&#227;o renal, fatores estes que, reconhecidamente, poderiam influenciar nas manifesta&#231;&#245;es cl&#237;nicas e nos n&#237;veis de BNP.</p>
    <p>Estes resultados diferem em alguns aspectos aos descritos na literatura. No estudo HF-ACTION, observou-se rela&#231;&#227;o entre as manifesta&#231;&#245;es cl&#237;nicas (mais acentuadas) nos pacientes com depress&#227;o em rela&#231;&#227;o aos n&#227;o deprimidos, mas n&#227;o se observou correla&#231;&#227;o entre medidas objetivas da fun&#231;&#227;o card&#237;aca e a presen&#231;a de depress&#227;o<sup>16</sup>. No entanto, em nosso estudo, constatamos uma n&#237;tida rela&#231;&#227;o entre a presen&#231;a de depress&#227;o grave e sinais objetivos de maior intensidade de congest&#227;o (n&#237;veis elevados de BNP). &#201; poss&#237;vel que a atua&#231;&#227;o sin&#233;rgica entre a IC e a depress&#227;o, assim como a presen&#231;a de um maior n&#250;mero de casos com depress&#227;o grave, tenha acentuado as manifesta&#231;&#245;es cl&#237;nicas a ponto de torn&#225;-las diferentes estatisticamente.</p>
    <p>De certo modo, esse menor comprometimento mioc&#225;rdico e a documenta&#231;&#227;o de maior congest&#227;o (BNP mais elevado) sinalizam a import&#226;ncia que tem a depress&#227;o na acentua&#231;&#227;o das manifesta&#231;&#245;es cl&#237;nicas dos pacientes deprimidos, uma vez que, mesmo com menor comprometimento card&#237;aco, apresentam mais manifesta&#231;&#245;es cl&#237;nicas. S&#227;o dados que explicam porque pacientes deprimidos hospitalizam-se mais do que os n&#227;o deprimidos.</p>
    <p>A postura dos pacientes em rela&#231;&#227;o &#224; doen&#231;a tamb&#233;m contribui para a g&#234;nese das manifesta&#231;&#245;es. Os pacientes deprimidos aderem menos &#224;s orienta&#231;&#245;es n&#227;o farmacol&#243;gicas (sal e restri&#231;&#227;o h&#237;drica) como tamb&#233;m &#224; obedi&#234;ncia ao tratamento medicamentoso<sup>15,16</sup>. A n&#227;o ader&#234;ncia ao tratamento &#233; um fator descrito cada vez mais como associado &#224; pior evolu&#231;&#227;o<sup>20-23</sup>.</p>
    <p>O conjunto de dados indica fortemente que a IC acentua ou provoca a depress&#227;o, mas o inverso tamb&#233;m &#233; verdadeiro. May e cols.<sup>9</sup>; estudando 13.708 pacientes com doen&#231;a coronariana sem IC ou depress&#227;o, puderam observar no seguimento que a IC surgiu em 3,6% dos pacientes sem depress&#227;o e em 16,4% dos deprimidos<sup>9</sup>. A depress&#227;o foi associada com risco 1,5 vezes maior do paciente vir a apresentar IC em rela&#231;&#227;o ao n&#227;o deprimido<sup>9</sup>.</p>
    <p>Em nosso estudo, pudemos tamb&#233;m documentar a IC como causa de depress&#227;o. Quando analisamos os valores de BNP e sua rela&#231;&#227;o com a incid&#234;ncia de depress&#227;o grave, pudemos constatar uma forte rela&#231;&#227;o entre os n&#237;veis mais elevados do BNP com uma maior incid&#234;ncia de quadros de depress&#227;o grave ou muito grave. Atrav&#233;s da curva <italic>ROC,</italic> identificamos valores acima de 1.100 pg/ml do BNP como o relacionado &#224; maior preval&#234;ncia de quadros depressivos, com 12,0 vezes mais chance desses pacientes com IC desenvolverem depress&#227;o grave do que aqueles com n&#237;veis mais baixos de BNP (<xref ref-type="fig" rid="f1">Figura 1</xref>).</p>
    <fig id="f1">
      <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gf01.jpg"/></fig>
    <p>Considerando-se que a depress&#227;o acentua as manifesta&#231;&#245;es cl&#237;nicas e piora a evolu&#231;&#227;o dos pacientes com IC, devemos os cl&#237;nicos dar mais aten&#231;&#227;o a ela, n&#227;o deixando de verificar se o portador de IC a apresenta. A import&#226;ncia de tal conduta vem crescendo, uma vez que h&#225; estudos documentando que, tratando-se a depress&#227;o, promove-se uma melhora nos sintomas e na qualidade de vida dos pacientes. Alguns estudos tamb&#233;m documentaram que tratar a depress&#227;o com antidepressivos pode reduzir a morbimortalidade dos portadores de IC<sup>21,24</sup>.</p>
    <p>A possibilidade de modificar a hist&#243;ria natural da doen&#231;a com o tratamento da depress&#227;o merece aten&#231;&#227;o. Nesta casu&#237;stica de pacientes com IC avan&#231;ada, a mortalidade hospitalar foi alta (27,9%), sendo que, nos pacientes com depress&#227;o grave ou muito grave, ela foi 2,38 vezes maior do que nos com depress&#227;o leve ou moderada (37,5% <italic>vs</italic> 15,7%; p = 0,115). Apesar da diferen&#231;a de mortalidade, ela n&#227;o foi significante. Esses resultados devem ser valorizados com cuidado em decorr&#234;ncia do tamanho da casu&#237;stica, mas s&#227;o concordantes com o que a literatura descreve quanto a pior evolu&#231;&#227;o dos pacientes com depress&#227;o<sup>25</sup>.</p>
    <p>Os resultados de nosso estudo demonstraram que os quadros depressivos graves s&#227;o frequentes entre os pacientes com IC avan&#231;ada e que sua presen&#231;a acentua as manifesta&#231;&#245;es da descompensa&#231;&#227;o card&#237;aca e sua gravidade. O estudo mostrou uma rela&#231;&#227;o da depress&#227;o com maior estimula&#231;&#227;o neuro-hormonal na IC avaliada pelo BNP, com a depress&#227;o acentuando a estimula&#231;&#227;o neuro-hormonal e a IC agravando a depress&#227;o.</p>
    <p>Conclu&#237;mos que, na IC avan&#231;ada, a preval&#234;ncia de depress&#227;o &#233; alta, que os pacientes com depress&#227;o apresentam n&#237;veis mais elevados de BNP do que os n&#227;o deprimidos, e que, quanto mais descompensado o paciente, maior a chance de vir a apresentar depress&#227;o grave ou muito grave. Esses resultados frente &#224; pequena casu&#237;stica estudada devem ser considerados como preliminares.</p>
    <p>A pesquisa da presen&#231;a de depress&#227;o vem sendo negligenciada entre os pacientes com IC, atitude que precisa ser modificada, pois a identifica&#231;&#227;o e o tratamento da depress&#227;o pode melhorar a qualidade de vida e a evolu&#231;&#227;o dos portadores de IC.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p>Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p>O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p>N&#227;o h&#225; vincula&#231;&#227;o deste estudo a programas de p&#243;s-gradua&#231;&#227;o.</p>
    <p>
      <fn id="back" fn-type="corresp">
        <p>Correspond&#234;ncia:</p>
        <p> Ant&#244;nio Carlos Pereira Barretto </p>
        <p> Rua Piave, 103, Morumbi </p>
        <p> 05620-010, S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="pbarreto@cardiol.br">pbarreto@cardiol.br</email>, </p>
        <p>
          <email xlink:href="pereira.barretto@incor.usp.br">pereira.barretto@incor.usp.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 26/10/09; revisado recebido em 09/04/10; aceito em 24/05/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. McMurray JJV,    Stewart S. The burden of heart failure. Eur Heart J. 2002; 4 (Suppl D): 50-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The burden of heart failure</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>50</fpage>
          <lpage>8</lpage>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>McMurray</surname>
              <given-names>JJV</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Pereira-Barretto    AC, Del Carlo CH, Cardoso JN, Novaes J, Morgado PC, Munhoz R, et al. Re-hospitaliza&#231;&#245;es    e morte por insufici&#234;ncia card&#237;aca. &#205;ndices ainda alarmantes.    Arq Bras Cardiol. 2008; 91 (5): 335-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Re-hospitaliza&#231;&#245;es e morte por insufici&#234;ncia card&#237;aca: &#205;ndices ainda alarmantes</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>335</fpage>
          <lpage>41</lpage>
          <issue>5</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Pereira-Barretto</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Del Carlo</surname>
              <given-names>CH</given-names>
            </name>
            <name>
              <surname>Cardoso</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Novaes</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Morgado</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Munhoz</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Bocchi EA, Braga    FGM, Ferreira SMA, Rohde LEP, Oliveira WA, Almeida DR, et al/Sociedade Brasileira    de Cardiologia. III Diretriz de insufici&#234;ncia card&#237;aca cr&#244;nica.    Arq Bras Cardiol. 2009; 93 (supl 1): 1-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>III Diretriz de insufici&#234;ncia card&#237;aca cr&#244;nica</article-title>
          <source>Arq Bras Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1</fpage>
          <lpage>71</lpage>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bocchi</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Braga</surname>
              <given-names>FGM</given-names>
            </name>
            <name>
              <surname>Ferreira</surname>
              <given-names>SMA</given-names>
            </name>
            <name>
              <surname>Rohde</surname>
              <given-names>LEP</given-names>
            </name>
            <name>
              <surname>Oliveira</surname>
              <given-names>WA</given-names>
            </name>
            <name>
              <surname>Almeida</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Joynt KE, Whellan    DJ, O'Connor CM . Why is depression bad for the failing heart? A review of the    mechanistic relationship between depression and heart failure. J Card Fail.    2004; 10 (3): 258-71.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Why is depression bad for the failing heart?: A review of the mechanistic relationship between depression and heart failure</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>258</fpage>
          <lpage>71</lpage>
          <issue>3</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Joynt</surname>
              <given-names>KE</given-names>
            </name>
            <name>
              <surname>Whellan</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>CM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Faris R, Purcel    H, Henein MY, Coats AJS. Clinical depression is common and significantly associated    with reduced survival and patients with non-ischaemic heart failure. Eur J Heart    Fail. 2002; 4 (4): 541-51.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical depression is common and significantly associated with reduced survival and patients with non-ischaemic heart failure</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>541</fpage>
          <lpage>51</lpage>
          <issue>4</issue>
          <volume>4</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Faris</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Purcel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Henein</surname>
              <given-names>MY</given-names>
            </name>
            <name>
              <surname>Coats</surname>
              <given-names>AJS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Frasure-Smith    N, Lesperance F, Habra M, Talajic M, Khairy P, Dorian P, et al. Elevated depression    symptoms predict long-term cardiovascular mortality in patients with atrial    fibrillation and heart failure. Circulation. 2009; 120 (2): 134-40.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Elevated depression symptoms predict long-term cardiovascular mortality in patients with atrial fibrillation and heart failure</article-title>
          <source>Circulation</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>134</fpage>
          <lpage>40</lpage>
          <issue>2</issue>
          <volume>120</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Frasure-Smith</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Lesperance</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Habra</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Talajic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khairy</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Dorian</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Junger J, Schellberg    D, Muller-Tasch T, Raupp G, Zugck C, Haunstetter A, et al. Depression increasingly    predicts mortality in the course of congestive heart failure. Eur J Heart Fail.    2005; 7 (2): 261-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depression increasingly predicts mortality in the course of congestive heart failure</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>261</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>7</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Junger</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Schellberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Muller-Tasch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Raupp</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zugck</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Haunstetter</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. Jiang W, Kuchibhatla    M, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, et al. Relationship between    depressive symptoms and long-term mortality in patients with heart failure.    Am Heart J. 2007; 154 (1): 102-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relationship between depressive symptoms and long-term mortality in patients with heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>102</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>154</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Jiang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Kuchibhatla</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Clary</surname>
              <given-names>GL</given-names>
            </name>
            <name>
              <surname>Cuffe</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Christopher</surname>
              <given-names>EJ</given-names>
            </name>
            <name>
              <surname>Alexander</surname>
              <given-names>JD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. May HT, Horne    BD, Carlquest JF Sheng X, Joy E, Catinella AP. Depression after coronary artery    disease is associated with heart failure. J Am Coll Cardiol. 2009; 53 (16):    1440-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depression after coronary artery disease is associated with heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1440</fpage>
          <lpage>7</lpage>
          <issue>16</issue>
          <volume>53</volume>
          <person-group person-group-type="author">
            <name>
              <surname>May</surname>
              <given-names>HT</given-names>
            </name>
            <name>
              <surname>Horne</surname>
              <given-names>BD</given-names>
            </name>
            <name>
              <surname>Carlquest JF Sheng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Joy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Catinella</surname>
              <given-names>AP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Albert NM,    Fonarow GC, Abraham WT, Gheorghiade M, Greenberg BH, Nunez E, et al. Depression    and clinical outcomes in heart failure: An OPTIMIZE-HF analysis. Am J Med. 2009;    122 (4): 366-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depression and clinical outcomes in heart failure: An OPTIMIZE-HF analysis</article-title>
          <source>Am J Med</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>366</fpage>
          <lpage>73</lpage>
          <issue>4</issue>
          <volume>122</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Albert</surname>
              <given-names>NM</given-names>
            </name>
            <name>
              <surname>Fonarow</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Abraham</surname>
              <given-names>WT</given-names>
            </name>
            <name>
              <surname>Gheorghiade</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Nunez</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Vaccarino V,    Karl SV, Abramson J, Krunholz HM. Depressive symptoms and risk of functional    decline and death in patients with heart failure. J Am Coll Cardiol. 2001; 38    (1): 199-205.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depressive symptoms and risk of functional decline and death in patients with heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>199</fpage>
          <lpage>205</lpage>
          <issue>1</issue>
          <volume>38</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Vaccarino</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Karl</surname>
              <given-names>SV</given-names>
            </name>
            <name>
              <surname>Abramson</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Krunholz</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Norra C, Skobel    EC, Arndt M, Schauerte P. High impact of depression in heart failure: early    diagnosis and treatment options. Int J Cardiol. 2008; 125 (2): 220-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>High impact of depression in heart failure: early diagnosis and treatment options</article-title>
          <source>Int J Cardiol</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>220</fpage>
          <lpage>31</lpage>
          <issue>2</issue>
          <volume>125</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Norra</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Skobel</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Arndt</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schauerte</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Runsfeld JS,    Havranek E, Masoudi FA, Peterson ED, Jones P, Tooley JF, et al. Depressive symptoms    are the strongest predictors of short-term declines in health status in patient    with heart failure. J Am Coll Cardiol. 2003; 42 (10): 1811-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depressive symptoms are the strongest predictors of short-term declines in health status in patient with heart failure</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>1811</fpage>
          <lpage>7</lpage>
          <issue>10</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Runsfeld</surname>
              <given-names>JS</given-names>
            </name>
            <name>
              <surname>Havranek</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Masoudi</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>ED</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Tooley</surname>
              <given-names>JF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Ferketich AK,    Fergusson JP, Binkley PF . Depressive symptoms and inflammation among heart    failure patients. Am Heart J. 2005; 150 (1): 132-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depressive symptoms and inflammation among heart failure patients</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>132</fpage>
          <lpage>6</lpage>
          <issue>1</issue>
          <volume>150</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ferketich</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Fergusson</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Binkley</surname>
              <given-names>PF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Morgan AL,    Masoudi FA, Havranek EP, Jones PG, Peterson PN, Krumholz HM, et al. Difficulty    taking medications, depression, and health datus in heart failure patients.    J Card Fail. 2006; 12 (1): 54-60.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Difficulty taking medications, depression, and health datus in heart failure patients</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>54</fpage>
          <lpage>60</lpage>
          <issue>1</issue>
          <volume>12</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Morgan</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Masoudi</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Havranek</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Jones</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Peterson</surname>
              <given-names>PN</given-names>
            </name>
            <name>
              <surname>Krumholz</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Gottlieb SS,    Kop WJ, Ellis SL, Binkley P, Howlett J, O'Connor C, et al. Relation of depression    to severity of illness in heart failure (HF-ACTION). Am J Cardiol. 2009; 103    (9): 1285-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Relation of depression to severity of illness in heart failure (HF-ACTION)</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>1285</fpage>
          <lpage>9</lpage>
          <issue>9</issue>
          <volume>103</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kop</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Ellis</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Binkley</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Howlett</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>O'Connor</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Sullivan M,    Lery WC, Russo JE, Spertus JA. Depression and health status in patients with    advanced heart failure: a prospective study in tertiary care. J Card Fail. 2004;    10 (5): 390-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depression and health status in patients with advanced heart failure: a prospective study in tertiary care</article-title>
          <source>J Card Fail</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>390</fpage>
          <lpage>6</lpage>
          <issue>5</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Sullivan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lery</surname>
              <given-names>WC</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Spertus</surname>
              <given-names>JA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Havranek EP,    Ware MG, Lowes BD. Prevalence of depression in congestive heart failure. Am    J Cardiol. 1999; 84 (3): 348-50.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prevalence of depression in congestive heart failure</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>348</fpage>
          <lpage>50</lpage>
          <issue>3</issue>
          <volume>84</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Havranek</surname>
              <given-names>EP</given-names>
            </name>
            <name>
              <surname>Ware</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Lowes</surname>
              <given-names>BD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Rutledge T,    Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure: a meta-analytic    review of prevalence, intervention effects, and association with clinical outcomes.    J Am Coll Cardiol. 2006; 48 (8): 1527-37.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depression in heart failure: a meta-analytic review of prevalence, intervention effects, and association with clinical outcomes</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1527</fpage>
          <lpage>37</lpage>
          <issue>8</issue>
          <volume>48</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rutledge</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Linke</surname>
              <given-names>SE</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>BH</given-names>
            </name>
            <name>
              <surname>Mills</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Wu JR, Moser    DK, Jong MJ, Rayens MK, Chung ML, Riegel B, et al. Defining an evidence-based    cutpoint for medication adherence in heart failure. Am Heart J. 2009; 157 (2):    285-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Defining an evidence-based cutpoint for medication adherence in heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2009</year>
          </date>
          <fpage>285</fpage>
          <lpage>91</lpage>
          <issue>2</issue>
          <volume>157</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Wu</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Moser</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Jong</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Rayens</surname>
              <given-names>MK</given-names>
            </name>
            <name>
              <surname>Chung</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Riegel</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Stork S, Hense    HW, Zentgraf C, Uebelacker I, Jahns R, Ertl G, et al. Pharmacotherapy according    to treatment guidelines is associated with lower mortality in a community-based    sample of patients with chronic heart failure: a prospective cohort study. Eur    J Heart Fail. 2008; 10 (12): 1236-45.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Pharmacotherapy according to treatment guidelines is associated with lower mortality in a community-based sample of patients with chronic heart failure: a prospective cohort study</article-title>
          <source>Eur J Heart Fail</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>1236</fpage>
          <lpage>45</lpage>
          <issue>12</issue>
          <volume>10</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stork</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hense</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>Zentgraf</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Uebelacker</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Jahns</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ertl</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Gislason GH,    Rasmussen JN, Abildstrom SR, Schramm TK, Hansen ML, Buch P, et al. Persistent    use of evidence based pharmacotherapy in heart failure is associated with improved    outcomes. Circulation. 2007; 116 (7): 737-44.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Persistent use of evidence based pharmacotherapy in heart failure is associated with improved outcomes</article-title>
          <source>Circulation</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>737</fpage>
          <lpage>44</lpage>
          <issue>7</issue>
          <volume>116</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gislason</surname>
              <given-names>GH</given-names>
            </name>
            <name>
              <surname>Rasmussen</surname>
              <given-names>JN</given-names>
            </name>
            <name>
              <surname>Abildstrom</surname>
              <given-names>SR</given-names>
            </name>
            <name>
              <surname>Schramm</surname>
              <given-names>TK</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Buch</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Parissis JT,    Nikolaou M, Farmakis D, Bistola V, Paraskevaidis IA, Adamopoulos S, et al. Clinical    and prognostic implications of self-rating depression scales and plasma B-type    natriuretic peptide in hospitalized patients with chronic heart failure. Heart.    2008; 94 (5): 585-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and prognostic implications of self-rating depression scales and plasma B-type natriuretic peptide in hospitalized patients with chronic heart failure</article-title>
          <source>Heart</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>585</fpage>
          <lpage>9</lpage>
          <issue>5</issue>
          <volume>94</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Parissis</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Nikolaou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Farmakis</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Bistola</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Paraskevaidis</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Adamopoulos</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Gottlieb SS,    Kop WJ, Thomas SA, Katzen S, Vesely MR, Greenberg N, et al. A double blind placebo    controlled pilot study of controlled-release paroxetine on depression and quality    of life in chronic heart failure. Am Heart J. 2007; 153 (5): 868-73.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A double blind placebo controlled pilot study of controlled-release paroxetine on depression and quality of life in chronic heart failure</article-title>
          <source>Am Heart J</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>868</fpage>
          <lpage>73</lpage>
          <issue>5</issue>
          <volume>153</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gottlieb</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Kop</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Thomas</surname>
              <given-names>SA</given-names>
            </name>
            <name>
              <surname>Katzen</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Vesely</surname>
              <given-names>MR</given-names>
            </name>
            <name>
              <surname>Greenberg</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Muller-Tasch    T, Petters-Klimm F, Schellberg D, Holzapfel N, Barth A, J&#252;nger J, et al.    Depression is a major determinant of quality of life in patients with chronic    heart failure in general practice. J Cardiac Fail. 2007; 13 (10): 818-24.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Depression is a major determinant of quality of life in patients with chronic heart failure in general practice</article-title>
          <source>J Cardiac Fail</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>818</fpage>
          <lpage>24</lpage>
          <issue>10</issue>
          <volume>13</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Muller-Tasch</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Petters-Klimm</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Schellberg</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Holzapfel</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Barth</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>J&#252;nger</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Relationship between depression, BNP levels and ventricular impairment in heart failure</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Depression is a common comorbidity in heart failure (HF); however, the mechanisms related to a poorer outcome of depressed patients with HF remain unclear. OBJECTIVE: To evaluate the role of severe depression in the outcome of patients with decompensated HF. METHODS: A total of 43 patients with advanced HF, EF &lt; 40.0%, and hospitalized for cardiac compensation were consecutively studied. After history taking and physical examination, the patients underwent laboratory tests including BNP determination. After the diagnosis of depression was made, the Hamilton-D scale was applied. Severe depression was defined by a score equal to or greater than 18. The clinical and laboratory variables according to the presence or absence of severe depression were analyzed using logistic regression. The ROC curve defined the cut-off point for BNP. RESULTS: Severe or very severe depression was identified in 24 (55.8%) patients. Severely depressed patients did not differ from non-depressed patients as regards age, gender and renal function, but showed less cardiac impairment (EF 23.4 &#177; 7.2% vs 19.5 &#177; 5.2%; p = 0.046) and higher BNP levels (2,582.8 &#177; 1,596.6 pg/ml vs 1,206.6 &#177; 587.0 pg/ml; p &lt; 0.001). However, patients with BNP levels higher than 1,100 pg/ml had a 12.0-fold higher chance (odds ratio [95% CI] = 2.61 - 55.26) of developing severe depression. CONCLUSION: Patients with severe depression showed a higher degree of neurohormonal stimulation despite their lower degree of ventricular dysfunction. The pathophysiological changes related to depression, leading to increased neurohormonal stimulation and cytokines, probably contributed to this more intense clinical manifestation even in the presence of less cardiac damage.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Depression</kwd>
        <kwd>comorbidity</kwd>
        <kwd>heart failure</kwd>
        <kwd>natriuretic peptides</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ORIGINAL ARTICLE</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Relationship between depression, BNP levels and ventricular impairment in heart failure</bold>
          </label>
          <p>
            <bold>Vera Barretto Aguiar; Marcelo Eidi Ochiai; Juliano Novais Cardoso; Carlos H Del Carlo; Paulo Cesar Morgado; Robinson Tadeu Munhoz; Antonio Carlos Pereira-Barretto</bold>
          </p>
        </fn>
      </p>
      <p>Hospital Auxiliar de Cotox&#243; - Instituto do Cora&#231;&#227;o - HC FMUSP, S&#227;o Paulo, SP - Brazil</p>
      <p>Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Depression is a common comorbidity in heart failure (HF); however, the mechanisms related to a poorer outcome of depressed patients with HF remain unclear.</p>
      <p><bold>OBJECTIVE:</bold> To evaluate the role of severe depression in the outcome of patients with decompensated HF.</p>
      <p><bold>METHODS:</bold> A total of 43 patients with advanced HF, EF &lt; 40.0%, and hospitalized for cardiac compensation were consecutively studied. After history taking and physical examination, the patients underwent laboratory tests including BNP determination. After the diagnosis of depression was made, the Hamilton-D scale was applied. Severe depression was defined by a score equal to or greater than 18. The clinical and laboratory variables according to the presence or absence of severe depression were analyzed using logistic regression. The ROC curve defined the cut-off point for BNP.</p>
      <p><bold>RESULTS:</bold> Severe or very severe depression was identified in 24 (55.8%) patients. Severely depressed patients did not differ from non-depressed patients as regards age, gender and renal function, but showed less cardiac impairment (EF 23.4 &#177; 7.2% <italic>vs</italic> 19.5 &#177; 5.2%; p = 0.046) and higher BNP levels (2,582.8 &#177; 1,596.6 pg/ml <italic>vs</italic> 1,206.6 &#177; 587.0 pg/ml; p &lt; 0.001). However, patients with BNP levels higher than 1,100 pg/ml had a 12.0-fold higher chance (odds ratio [95% CI] = 2.61 - 55.26) of developing severe depression.</p>
      <p><bold>CONCLUSION:</bold> Patients with severe depression showed a higher degree of neurohormonal stimulation despite their lower degree of ventricular dysfunction. The pathophysiological changes related to depression, leading to increased neurohormonal stimulation and cytokines, probably contributed to this more intense clinical manifestation even in the presence of less cardiac damage.</p>
      <p><bold>Key words:</bold> Depression; comorbidity; heart failure; natriuretic peptides/analysis.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Heart failure (HF) is known to be a syndrome accompanied by high morbidity and mortality<sup>1-3</sup>. Both morbidity and mortality are influenced by the comorbidities of the patients, and patients with comorbidities, among which is depression, have a poorer outcome<sup>1,3</sup>.</p>
      <p>In the overall population, from 5.0% to 10.0% of the individuals have criteria for the diagnosis of depression. Among patients with heart failure seen in outpatient clinics, this prevalence is of between 11.0% and 25%, and among those hospitalized with HF, the rate increases to the range of 35.0% to 70.0%<sup>4</sup>. The wide variation in the incidence results from the different techniques used for the diagnosis, as well as from the characteristics of the study populations, considering age, gender and severity of HF<sup>5</sup>. Anyway, a strong association between HF and depression is observed<sup>6-13</sup>.</p>
      <p>HF and depression share common pathophysiological aspects, both increasing the stimulation of the hypothalamus-pituitary-adrenal axis and the sympathetic activity, as well as increasing the levels of circulating inflammatory cytokines<sup>14-17</sup>. Depression can contribute to the development of HF in susceptible populations and aggravate the manifestations of HF in those with existing disease, and is predictive of re-hospitalizations and mortality<sup>6,7,10,11</sup>.</p>
      <p>The high morbidity and mortality may be related to the synergistic action between HF and depression on neurohormonal activation; to inflammatory factors; and to hypercoagulability<sup>5,14,15</sup>. Depression also has a negative influence on the course of HF, for being associated with patient non-compliance with medical recommendations, especially as regards the use of medications<sup>15-17</sup>. Patients with HF and depression are more symptomatic, presenting with more advanced functional class and frequently a poorer quality of life.</p>
      <p>In view of these findings, we sought to verify the role of severe depression in the clinical presentation of patients with advanced HF admitted in a tertiary hospital for cardiac compensation.</p>
      <p>
        <bold>Methods</bold>
      </p>
      <p>In a large tertiary hospital in the city of S&#227;o Paulo, we conducted a cross-sectional study including 43 consecutive patients hospitalized for compensation of heart failure and for whom psychiatric evaluation had been requested by the clinician. Psychiatric evaluation is performed at the discretion of the patient's clinician, and not routinely for all patients.</p>
      <p>At hospital admission, all patients were clinically assessed and underwent laboratory tests including complete blood count, hematocrit, and determination of serum levels of BUN, creatinine, sodium, potassium, and B-type natriuretic peptide (BNP).</p>
      <p>Patients with left ventricular ejection fraction &lt; 0.40 for whom a psychiatric evaluation had been requested by the clinician were included in the study. The exclusion criteria were delirium; dementia; psychosis; bipolar affective disorders; sepsis; neoplasias; and baseline creatinine &gt; 3.0 mg/dl.</p>
      <p>Left ventricular ejection fraction (LVEF) was calculated by means of echocardiographic study using the Teichholz method or Simpson's rule performed within six months prior to hospitalization. BNP was determined by chemiluminescence immunoassay, ADVIA Centaur&#153; system (Roche Inc.), and was expressed as pg/ml.</p>
      <p>Patients meeting the inclusion criteria and not meeting the exclusion criteria underwent depression assessment using the 17-item version Hamilton-D depression assessment rating scale. In this scale, the patients were classified as follows:</p>
      <p>- from 0 to 7 points, normal;</p>
      <p>- from 8 to 13 points, patients with mild depression;</p>
      <p>- from 14 to 18 points, moderate depression;</p>
      <p>- from 19 to 22 points, severe depression; and</p>
      <p>- 23 or more points, very severe depression.</p>
      <p>According to the result of the assessment of presence of depression, the patients were divided into two groups: group 1 - comprising patients with less than 18 points in the Hamilton scale (euthymia or mild and moderate depression), and group 2 - comprising patients with a score higher than 18 (severe or very severe depression).</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Categorical variables were expressed as proportion and percentage, and continuous variables as mean and standard deviation.</p>
      <p>Comparisons between continuous variables were made using the Student's t test. The chi square test or Fisher's exact test were used to analyze the categorical variables. The ROC curve was constructed to analyze the best cut-off point between BNP levels and the assessment of intensity of depression. Univariate and multiple logistic regression analyses were used to determine predictors of depression. Variables with p &lt; 0.200 in the univariate analysis were included in the multivariate analysis. The final model was constructed using the stepwise forward procedure. In the final model, variables with p &lt; 0.05 were maintained.</p>
      <p>In the comparisons, differences with p values &lt; 0.05 were considered significant.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p><xref ref-type="table" rid="t1-body2">Table 1</xref> shows the main clinical characteristics of the patients.</p>
      <table-wrap id="t1-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt01-en.jpg"/></table-wrap>
      <p>The mean age of the patients was 54.3 &#177; 15.9 years.</p>
      <p>In this population, all patients were in NYHA functional class IV, the mean LVEF was 21.6 &#177; 6.6, and the mean BNP level was 1.974 &#177; 1,421.9 pg/ml. These findings characterize the participants as patients with advanced HF.</p>
      <p>It was also observed that most of the patients with HF and systolic ventricular dysfunction hospitalized for compensation presented with severe or very severe depression (24 patients - 55.8%).</p>
      <p>Results of the variables according to the presence or absence of severe or very severe depression are shown in <xref ref-type="table" rid="t2-body2">Table 2</xref>.</p>
      <table-wrap id="t2-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt02-en.jpg"/></table-wrap>
      <p>Patients with severe or very severe depression did not differ from those without depression or with mild and moderate depression as regards age, gender, and renal function, but they presented with less cardiac impairment (LVEF 23.4 &#177; 7.2% <italic>vs</italic> 19.5 &#177; 5.2%; p = 0.046) and higher BNP levels (2,582.8 &#177; 1,596.6 pg/ml <italic>vs</italic> 1,206.6 &#177; 587.0 pg/ml; p &lt; 0.001).</p>
      <p>In face of the difference in BNP levels between the patients with severe or very severe depression and the others, an ROC curve was constructed which identified the BNP level of 1,100 pg/ml as the best cut-off point (Area under the curve = 0.79), with sensitivity = 87.5% and specificity = 63.2%.</p>
      <p>In the logistic regression analysis, BNP was the only independent variable related to an increased risk of severe depression, and patients with BNP <underline>&gt;</underline> 1,100 pg/ml had a 12-fold higher chance of developing severe depression (<xref ref-type="table" rid="t3-body2">Table 3</xref>).</p>
      <table-wrap id="t3-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt03-en.jpg"/></table-wrap>
      <p>In the study population, 12/43 (27.9%) patients died during hospitalization; 3/19 (15.7%) were from the group with mild to moderate depression and 9/24 (37.5%) from the group with severe or very severe depression (p = 0.115). In the follow-up 90 days after hospitalization, three more deaths were observed, one in the group with mild to moderate depression and two in the group with more severe depression. In all, by the end of 90 days, 15/43 (34.8%) patients died, 4/19 (21.0%) in the group with mild to moderate depression and 11/24 (45.8%) in the group with severe or very severe depression (p = 0.090).</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>High morbidity and mortality are observed in advanced forms of HF<sup>1-3</sup>. The presence of comorbidities may worsen the outcome of the patients, thus further increasing morbidity and mortality, which are already high<sup>3</sup>.</p>
      <p>The presence of anemia, atrial fibrillation, thyroid dysfunction, chronic obstructive pulmonary disease and depression are known to be factors associated with a poorer prognosis<sup>3</sup>.</p>
      <p>Depression is a multifaceted condition. Havranek et al<sup>18</sup> identified four independent factors associated with the development of depression: living alone, alcohol abuse, financial losses, and worsening of HF<sup>18</sup>. The loss of social support is identified as one of the most important factors for depression, increasing its risk by 3.2 times in men and 8 times in women<sup>18</sup>.</p>
      <p>Depression has not been systematically analyzed in patients with HF, but, when studied, it is verified to be relatively common among these patients<sup>6-13</sup>. In patients without HF, major depressive manifestations are described in 14.0%-26.0% of the individuals; however, in patients with HF, this incidence rises to 24.0%-85.0% of the patients<sup>4</sup>. The prevalence of depression increases with age, but is clearly aggravated by the presence of HF. Not only does the incidence of depression increase with the presence of HF, but it is also related to its severity, being more frequent in more symptomatic HF<sup>11,12,19</sup>. Thus, the frequency of depressive disorders is higher among cohorts of hospitalized patients than among outpatients, probably as a reflex of the greater severity of HF in hospitalized patients<sup>6-13,19</sup>. Mild depression may be found in most of the patients hospitalized for cardiac decompensation, affecting 85.0% of them. Severe depression is less frequent<sup>12</sup>.</p>
      <p>Not only is depression commonly seen in patients with HF, but also patients with HF and depression have a two to three-fold higher risk of death. Depressed patients are also hospitalized approximately three times more frequently, and depression does not resolve in one third of the patients in the first year of follow-up. Depression increases the costs of treatment by 25.0%-40.0%, as well as hospitalization rates, and is associated with worsened functional class and impaired daily activities<sup>12</sup>.</p>
      <p>In the present study, we sought to evaluate the relationship between HF and depression in patients with advanced HF. The diagnosis of depression is made by means of a psychiatric assessment, and the Hamilton-D scale helps classify the severity of the disease by turning the assessment into figures, which is useful in scientific research<sup>6,8,10,12,14,15</sup>. With this test, the severity of depression is scored; the higher the score, the more severe the disease. In the present study, we applied the Hamilton-D scale because of its accuracy in the diagnosis of depression and its easy way to graduate depression, as well as for having demonstrated (in several studies) that it evaluates the degree of severity in crises of depression.</p>
      <p>Our case series comprised patients with advanced HF. In <italic>Hospital Auxiliar de Cotox&#243;</italic>, a severity bias occurs, because only patients who could not be compensated or who did not improve in the emergency room are admitted<sup>2</sup>. In this population, 55.8% of the patients presented with signs of severe or very severe depression, as identified by the Hamilton-D scale which showed scores higher than 18.</p>
      <p>When we compared our data to those of the literature, we observed that the incidence of severe depression among our patients was higher than that described in published studies on patients with HF<sup>8,12,15</sup>. The characteristics of our population comprised of patients with very advanced HF may be an explanation to this finding, because of the strong correlation between severity of HF and the incidence and severity of depression. The pathophysiology, with aspects common to HF and depression, may explain this finding, since both HF and depression lead to the elevation of neurohormone and cytokine levels so that, by acting together, they enhance the pathophysiological changes, which, in turn, exacerbate clinical manifestations, morbidity and mortality<sup>13-17,19</sup>.</p>
      <p>However, in our study, when patients with severe depression (Hamilton-D score &gt; 18) were compared to those without depression or with mild to moderate depression, it was interesting to observe that those with severe or very severe depression showed higher BNP levels (2,582.8 &#177; 1,596.6 pg/ml <italic>vs</italic> 1,206.6 &#177; 587.0 pg/ml; p &lt; 0.001). This indicates more severe manifestations of congestion, in contrast to higher ejection fraction values (33.4 &#177; 7.2% <italic>vs</italic> 19.5 &#177; 5.2%; p = 0.046), which indicates less ventricular impairment<sup>12,13,17-19</sup>. These data may be considered as a documentation of the previously mentioned synergy between HF and depression in the genesis of the clinical manifestations of patients with the disease.</p>
      <p>It is important to point out that there were no differences between the two groups as regards gender, age, anemia, and renal function, which are factors known to exert influence on the clinical manifestations and BNP levels.</p>
      <p>In relation to some aspects these results are different from those described in the literature. In the HF-ACTION study, a relationship was observed between clinical manifestations (more severe) in patients with depression in comparison to non-depressed patients, but no correlation was observed between objective measurements of the cardiac function and the presence of depression<sup>16</sup>. However, in our study, we verified a clear relationship between the presence of severe depression and objective signs of more severe congestion (high BNP levels). The synergistic action between HF and depression, as well as the presence of a greater number of cases of severe depression, may possibly have exacerbated the clinical manifestations to the point of making them statistically different.</p>
      <p>To a certain extent, this lesser myocardial impairment and the documentation of more severe congestion (higher BNP levels) show the importance of depression in the exacerbation of the clinical manifestation of depressed patients because even with less cardiac impairment they present with more clinical manifestations. This explains why depressed patients are more frequently hospitalized than non-depressed patients.</p>
      <p>The attitude of the patients in relation to their disease also contributes to the genesis of the manifestations. Depressed patients are less compliant with non-pharmacological advices (salt ingestion and fluid restriction) as well as with the pharmacological treatment<sup>15,16</sup>. Non-compliance with treatment is increasingly described as being associated with a poorer outcome<sup>20-23</sup>.</p>
      <p>The pool of data strongly suggests that HF exacerbates or triggers depression, but the converse is also true. May et al<sup>9</sup> studied 13,708 patients with coronary artery disease without HF or depression and observed that HF developed in 3.6% of the non-depressed patients and in 16.4% of the depressed patients during the follow-up<sup>9</sup>. Depression was associated with a 1.5-fold higher risk of the patient further presenting with HF in relation to non-depressed patients<sup>9</sup>.</p>
      <p>In our study, we could also demonstrate HF as the cause of depression. When BNP levels and their relation to the incidence of severe depression were analyzed, we could verify a strong correlation between higher BNP levels and a higher incidence of severe or very severe depression. Using the ROC curve, we identified that BNP levels higher than1,100 pg/ml were associated with a higher prevalence of depressive symptoms, with a 12.0-fold higher chance of these patients with HF developing severe depression in comparison to those with lower BNP levels (<xref ref-type="fig" rid="f1-body2">Figure 1</xref>).</p>
      <fig id="f1-body2">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gf01-en.jpg"/></fig>
      <p>Considering that depression exacerbates the clinical manifestations and worsens the outcome of patients with HF, we clinicians should pay more attention to it, and never fail to investigate whether patients with HF also present with depression. The importance of this approach has increasingly being considered, and now there are studies showing that, by treating depression, improvement of symptoms and a better quality of life for the patients are achieved. Some studies also showed that treating depression with antidepressant drugs may reduce the morbidity and mortality of patients with HF<sup>21,24</sup>.</p>
      <p>The possibility of changing the natural history of the HF by treating depression is worthy of attention. In our case series of patients with advanced HF, in-hospital mortality was high (27.9%); among patients with severe or very severe depression it was 2.38 times higher than among those with mild or moderate depression (37.5% <italic>vs</italic> 15.7%; p = 0.115). Despite the difference in mortality, it was not statistically significant. These results should be carefully considered in view of the sample size; however, they are consistent with reports of the literature regarding the worse outcome of patients with depression.</p>
      <p>Our results showed that severe depressive manifestations are frequent among patients with advanced HF and that their presence exacerbates the symptoms of cardiac decompensation as well as its severity. This study showed a relationship between depression and more neurohormonal stimulation in HF as assessed by BNP, with depression exacerbating the neurohormonal stimulation and HF worsening depression<sup>25</sup>.</p>
      <p>In conclusion, the prevalence of depression in advanced HF is high; patients with depression show higher BNP levels than non-depressed patients; and the more decompensated the patient, the higher their chance of developing severe or very severe depression. Given the small sample size, these findings should be considered as preliminary.</p>
      <p>Investigation of the presence of depression has been overlooked among patients with HF and this should be changed, since the identification and treatment of depression may improve both the quality of life and the outcome of patients with HF.</p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p>No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p>There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p>This study is not associated with any post-graduation program.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="es">Relaci&#243;n entre depresi&#243;n, nivel de bnp y compromiso ventricular en la insuficiencia card&#237;aca</article-title>
      </title-group>
      <abstract xml:lang="es">
        <p>FUNDAMENTO: La depresi&#243;n es una comorbilidad frecuente en la insuficiencia card&#237;aca (IC), pero los mecanismos relacionados a peor evoluci&#243;n de pacientes deprimidos con IC aun no est&#225;n aclarados. OBJETIVO: Evaluar el papel de la depresi&#243;n grave en la evoluci&#243;n de los pacientes con IC descompensada. M&#201;TODOS: Estudiamos consecutivamente 43 pacientes con IC avanzada y FE &lt; 40,0%, hospitalizados para compensaci&#243;n card&#237;aca. Los pacientes, despu&#233;s de historia y examen f&#237;sico, fueron sometidos a ex&#225;menes de laboratorio, incluyendo el dosaje de BNP. Despu&#233;s del diagn&#243;stico de depresi&#243;n, se aplic&#243; la escala de Hamilton-D. Depresi&#243;n grave fue definida por escore igual o mayor que 18. Las variables cl&#237;nicas-de laboratorio, seg&#250;n la presencia o no de depresi&#243;n grave, fueron analizadas por la regresi&#243;n log&#237;stica. La curva ROC defini&#243; el punto de corte para el BNP. RESULTADOS: Depresi&#243;n grave o muy grave fue identificada en 24 (55,8%) pacientes. Los pacientes deprimidos graves no difirieron de los no deprimidos en cuanto a la edad, sexo y funci&#243;n renal, pero presentaron menor compromiso card&#237;aco (FE 23,4 &#177; 7,2% vs. 19,5 &#177; 5,2%; p = 0,046) y valores m&#225;s elevados del BNP (2.582,8 &#177; 1.596,6 pg/ml vs. 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001). Mientras tanto, los pacientes con BNP mayor que 1.100 pg/ml tuvieron 12,0 (odds ratio [IC 95%] = 2,61 - 55,26) veces m&#225;s chance de desarrollar cuadros de depresi&#243;n grave. CONCLUS&#205;ON: Los pacientes con depresi&#243;n grave presentaron mayor grado de estimulaci&#243;n neurohormonal, a pesar del grado de disfunci&#243;n ventricular ser menor. Las alteraciones fisiopatol&#243;gicas relacionadas a la depresi&#243;n, aumentando la estimulaci&#243;n neurohormonal y las citocinas, probablemente contribuyeron a esa mayor manifestaci&#243;n cl&#237;nica, aun en presencia de menor da&#241;o card&#237;aco.</p>
      </abstract>
      <kwd-group xml:lang="es">
        <kwd>Depresi&#243;n</kwd>
        <kwd>comorbilidad</kwd>
        <kwd>insuficiencia card&#237;aca</kwd>
        <kwd>p&#233;ptidos natriur&#233;ticos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body3">
          <label>
            <bold>Relaci&#243;n entre depresi&#243;n, nivel de bnp y compromiso ventricular en la insuficiencia card&#237;aca</bold>
          </label>
          <p>
            <bold>Vera Barretto Aguiar; Marcelo Eidi Ochiai; Juliano Novais Cardoso; Carlos H Del Carlo; Paulo Cesar Morgado; Robinson Tadeu Munhoz; Antonio Carlos Pereira-Barretto</bold>
          </p>
        </fn>
      </p>
      <p>Hospital Auxiliar de Cotox&#243; - Instituto do Cora&#231;&#227;o - HC FMUSP, S&#227;o Paulo, SP - Brasil</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMO</bold>
      </p>
      <p><bold>FUNDAMENTO: </bold> La depresi&#243;n es una comorbilidad frecuente en la insuficiencia card&#237;aca (IC), pero los mecanismos relacionados a peor evoluci&#243;n de pacientes deprimidos con IC aun no est&#225;n aclarados.</p>
      <p><bold>OBJETIVO:</bold> Evaluar el papel de la depresi&#243;n grave en la evoluci&#243;n de los pacientes con IC descompensada.</p>
      <p><bold>M&#201;TODOS:</bold> Estudiamos consecutivamente 43 pacientes con IC avanzada y FE &lt; 40,0%, hospitalizados para compensaci&#243;n card&#237;aca. Los pacientes, despu&#233;s de historia y examen f&#237;sico, fueron sometidos a ex&#225;menes de laboratorio, incluyendo el dosaje de BNP. Despu&#233;s del diagn&#243;stico de depresi&#243;n, se aplic&#243; la escala de Hamilton-D. Depresi&#243;n grave fue definida por escore igual o mayor que 18. Las variables cl&#237;nicas-de laboratorio, seg&#250;n la presencia o no de depresi&#243;n grave, fueron analizadas por la regresi&#243;n log&#237;stica. La curva ROC defini&#243; el punto de corte para el BNP.</p>
      <p><bold>RESULTADOS: </bold> Depresi&#243;n grave o muy grave fue identificada en 24 (55,8%) pacientes. Los pacientes deprimidos graves no difirieron de los no deprimidos en cuanto a la edad, sexo y funci&#243;n renal, pero presentaron menor compromiso card&#237;aco (FE 23,4 &#177; 7,2% vs. 19,5 &#177; 5,2%; p = 0,046) y valores m&#225;s elevados del BNP (2.582,8 &#177; 1.596,6 pg/ml vs. 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001). Mientras tanto, los pacientes con BNP mayor que 1.100 pg/ml tuvieron 12,0 (odds ratio [IC 95%] = 2,61 - 55,26) veces m&#225;s chance de desarrollar cuadros de depresi&#243;n grave.</p>
      <p><bold>CONCLUS&#205;ON:</bold> Los pacientes con depresi&#243;n grave presentaron mayor grado de estimulaci&#243;n neurohormonal, a pesar del grado de disfunci&#243;n ventricular ser menor. Las alteraciones fisiopatol&#243;gicas relacionadas a la depresi&#243;n, aumentando la estimulaci&#243;n neurohormonal y las citocinas, probablemente contribuyeron a esa mayor manifestaci&#243;n cl&#237;nica, aun en presencia de menor da&#241;o card&#237;aco. </p>
      <p><bold>Palabras clave: </bold> Depresi&#243;n, comorbilidad, insuficiencia card&#237;aca, p&#233;ptidos natriur&#233;ticos / an&#225;lisis.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La insuficiencia card&#237;aca (IC) es reconocida como un s&#237;ndrome que cursa con alta morbilidad y mortalidad<sup>1-3</sup>. Tanto la morbilidad como la mortalidad sufren la influencia de las comorbilidades que los pacientes presentan y pacientes con comorbilidades, entre ellas la depresi&#243;n, evolucionan peor<sup>1,3</sup>.</p>
      <p>En la poblaci&#243;n en general, de 5,0% a 10,0% de los individuos presentan criterios para el diagn&#243;stico de depresi&#243;n. En portadores de insuficiencia card&#237;aca atendidos en ambulatorios, esa prevalencia est&#225; entre 11,0% a 25,0%, y en pacientes con IC hospitalizados, aumenta para la franja de 35,0% a 70,0%4. La amplia variaci&#243;n en la incidencia es consecuencia de las diferentes t&#233;cnicas empleadas para el diagn&#243;stico, as&#237; como de las caracter&#237;sticas de las poblaciones estudiadas, consider&#225;ndose la edad, sexo y la intensidad de la IC<sup>5</sup>. De cualquier manera, se observa una fuerte asociaci&#243;n entre la IC y depresi&#243;n<sup>6-13</sup>.</p>
      <p>La IC y la depresi&#243;n tienen aspectos fisiopatol&#243;gicos comunes, ambas aumentando la estimulaci&#243;n del eje hipot&#225;lamo - hip&#243;fisis adrenal y la actividad simp&#225;tica, bien como aumentando las citocinas inflamatorias circulantes<sup>14-17</sup>. La depresi&#243;n puede contribuir para el desarrollo de la IC en poblaci&#243;n susceptible, como tambi&#233;n agravar cuadros de IC en aquellos con la enfermedad ya instalada, siendo un predictor de rehospitalizaciones y de mortalidad<sup>6,7,10,11</sup>.</p>
      <p>La alta morbimortalidad puede estar relacionada a la acci&#243;n sin&#233;rgica entre la IC y la depresi&#243;n en la activaci&#243;n neurohormonal, a factores inflamatorios y a la hipercoagulabilidad<sup>5,14,15</sup>. La depresi&#243;n aun influencia negativamente la evoluci&#243;n de la IC por estar asociada a la no adherencia de los pacientes a las recomendaciones m&#233;dicas, en especial a la toma de las medicaciones<sup>15-17</sup>. Los pacientes con IC deprimidos son m&#225;s sintom&#225;ticos, present&#225;ndose en clase funcional m&#225;s elevada y, con frecuencia, tienen peor calidad de vida.</p>
      <p>Frente a estos hallazgos, procuramos verificar el papel de la depresi&#243;n grave en el cuadro cl&#237;nico de los pacientes con IC avanzada internados, en un hospital terciario, para compensaci&#243;n card&#237;aca.</p>
      <p>
        <bold>M&#233;todos</bold>
      </p>
      <p>En un grande hospital terciario de la ciudad de S&#227;o Paulo, realizamos un estudio transversal que incluy&#243; consecutivamente 43 pacientes hospitalizados para compensaci&#243;n de insuficiencia card&#237;aca, para los cuales fue solicitada evaluaci&#243;n psiqui&#225;trica por el cl&#237;nico. La evaluaci&#243;n psiqui&#225;trica es realizada a criterio del cl&#237;nico del paciente, no siendo realizaci&#243;n de rutina para todos los pacientes.</p>
      <p>En la llegada al hospital, todos los pacientes fueron evaluados cl&#237;nicamente y sometidos a la evaluaci&#243;n de laboratorio, que inclu&#237;a un hemograma, hematocrito, dosaje s&#233;rico de urea, creatinina, sodio, potasio y dosaje del p&#233;ptido natriur&#233;tico del tipo B (BNP).</p>
      <p>Fueron incluidos en el estudio pacientes con fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo &lt; 0,40, para los cuales fue solicitada evaluaci&#243;n psiqui&#225;trica por el cl&#237;nico. Fueron criterios de exclusi&#243;n: <italic>delirium</italic>, demencia, psicosis, trastornos afectivos bipolares, sepsis, neoplasias y creatinina basal &gt; 3,0 mg/dl.</p>
      <p>La fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI) fue calculada a trav&#233;s de estudio ecocardiogr&#225;fico, emple&#225;ndose el m&#233;todo de Teichholz o Simpson, realizados por lo menos en los 6 meses previos a la internaci&#243;n. El dosaje de BNP fue realizado por el m&#233;todo inmunoensayo por quimioluminiscencia, sistema ADVIA Centaur<sup>&#174;</sup> (Roche Inc.), expresada en pg/ml.</p>
      <p>Los pacientes que presentaban los criterios de inclusi&#243;n y no presentaban los criterios de exclusi&#243;n fueron sometidos a evaluaci&#243;n de la depresi&#243;n a trav&#233;s de la escala de evaluaci&#243;n de depresi&#243;n de Hamilton - D, versi&#243;n 17 &#237;tems. En esa escala, los pacientes son considerados de la siguiente forma:</p>
      <disp-quote>
        <p>- de 0 la 7 puntos, normales;</p>
        <p>- de 8 la 13 puntos, portadores de depresi&#243;n leve;</p>
        <p>- de 14 la 18 puntos, con depresi&#243;n moderada;</p>
        <p>- de 19 la 22 puntos, con depresi&#243;n grave; y</p>
        <p>- 23 el m&#225;s puntos, con depresi&#243;n muy grave.</p>
      </disp-quote>
      <p>De acuerdo con el resultado de la evaluaci&#243;n de la presencia de depresi&#243;n, los pacientes fueron divididos en dos grupos: grupo 1 - constituido por los pacientes con menos de 18 en la escala del test de Hamilton (eut&#237;micos o depresi&#243;n leve y moderada) y grupo 2 - constituido por los pacientes con escore mayor de 18 (depresi&#243;n grave o muy grave).</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Las variables categ&#243;ricas fueron expresadas con proporci&#243;n y porcentaje y las variables continuas fueron expresadas con media y desv&#237;o-est&#225;ndar.</p>
      <p>Las comparaciones entre las variables continuas fueron analizadas por el test t de <italic>Student</italic>. El test del qui-cuadrado o el test Exacto de <italic>Fisher</italic> fueron utilizados para evaluar las variables categ&#243;ricas. Se construyo la curva ROC para an&#225;lisis del mejor punto de corte entre los niveles de BNP y la evaluaci&#243;n de la intensidad de la depresi&#243;n. El an&#225;lisis de regresi&#243;n log&#237;stica univariado y m&#250;ltiple fue utilizado para determinaci&#243;n de los predictores de depresi&#243;n. Las variables con p &lt; 0,200 en el an&#225;lisis univariado fueron incluidas en el an&#225;lisis multivariado. El modelo final fue construido con el procedimiento <italic>stepwise forward</italic>. En el modelo final, permanecieron las variables con p &lt; 0,05.</p>
      <p>En las comparaciones, las diferencias con valor de p &lt; 0,05 fueron consideradas como significativas.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>En la <xref ref-type="table" rid="t1-body3">Tabla 1</xref>, presentamos las principales caracter&#237;sticas cl&#237;nicas de los pacientes.</p>
      <table-wrap id="t1-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt01-es.jpg"/></table-wrap>
      <p>La edad media de los pacientes fue de 54,3 &#177; 15,9 a&#241;os.</p>
      <p>En esa poblaci&#243;n, todos se encontraban en clase funcional IV (NYHA), la FEVI media fue de 21,6 &#177; 6,6 y el dosaje de BNP de 1.974 &#177; 1.421,9 pg/ml. Tales hallazgos caracterizan los pacientes como portadores de IC avanzada.</p>
      <p>Se constat&#243; tambi&#233;n que la mayor&#237;a de los pacientes con IC y disfunci&#243;n ventricular sist&#243;lica internados para compensaci&#243;n presentaba cuadro de depresi&#243;n grave o muy grave (24 pacientes - 55,8%).</p>
      <p>En la <xref ref-type="table" rid="t2-body3">Tabla 2</xref>, presentamos los resultados de las variables seg&#250;n la presencia o no de depresi&#243;n grave o muy grave.</p>
      <table-wrap id="t2-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt02-es.jpg"/></table-wrap>
      <p>Los pacientes con depresi&#243;n grave o muy grave no difirieron de los sin depresi&#243;n o con depresi&#243;n leve y moderada en cuanto a la edad, sexo y funci&#243;n renal, pero presentaron menor compromiso card&#237;aco (FEVI 23,4 &#177; 7,2% vs. 19,5 &#177; 5,2%; p = 0,046) y valores m&#225;s elevados del BNP (2.582,8 &#177; 1.596,6 pg/ml vs. 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001).</p>
      <p>Frente a la diferencia en los valores de BNP entre los pacientes con depresi&#243;n grave o muy grave y los otros, se construy&#243; la curva ROC que identific&#243;, como el mejor nivel de corte, el valor de BNP de 1.100 pg/ml (&#193;rea bajo la curva = 0,79), con sensibilidad = 87,5% y especificidad = 63,2%.</p>
      <p>En el an&#225;lisis de regresi&#243;n log&#237;stica, el BNP fue la &#250;nica variable independiente relacionada con el aumento de riesgo de depresi&#243;n grave, siendo que los pacientes con BNP <underline>&gt;</underline> 1.100 pg/mL presentaron chance 12,0 veces mayor de desarrollaron depresi&#243;n grave (<xref ref-type="table" rid="t3-body3">Tabla 3</xref>).</p>
      <table-wrap id="t3-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gt03-es.jpg"/></table-wrap>
      <p>En esa poblaci&#243;n estudiada, 12/43 (27,9%) pacientes murieron durante la hospitalizaci&#243;n, siendo 3/19 (15,7%) del grupo con depresi&#243;n leve a moderada y 9/24 (37,5%) en el grupo con depresi&#243;n grave o muy grave (p = 0,115). En el seguimiento de 90 d&#237;as despu&#233;s de la internaci&#243;n, ocurrieron tres muertes m&#225;s, una en el grupo con depresi&#243;n leve a moderada y dos en el grupo con depresi&#243;n m&#225;s intensa. En el total, al final de 90 d&#237;as, 15/43 (34,8%) pacientes fallecieron, siendo 4/19 (21,0%) en el grupo con depresi&#243;n leve y moderada y 11/24 (45,8%) en el grupo con depresi&#243;n grave o muy grave (p = 0,090).</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La IC es una enfermedad que, en las formas avanzadas, evoluciona con alta morbimortalidad<sup>1-3</sup>. La presencia de comorbilidades puede empeorar la evoluci&#243;n de los pacientes, aumentando aun m&#225;s la ya elevada morbimortalidad<sup>3</sup>.</p>
      <p>Son reconocidos como factores asociados al peor pron&#243;stico la presencia de anemia, de fibrilaci&#243;n atrial, disfunci&#243;n tiroidea, de enfermedad pulmonar obstructiva cr&#243;nica y de depresi&#243;n<sup>3</sup>.</p>
      <p>La depresi&#243;n es enfermedad de muchos aspectos. Havranek y cols<sup>18</sup> identific&#243; 4 factores independientes relacionados al desarrollo de depresi&#243;n: vivir solo, abuso de alcohol, p&#233;rdida financiera y empeoramiento de la IC<sup>18</sup>. La p&#233;rdida de soporte social es identificada como uno de los m&#225;s importantes factores para la depresi&#243;n, aumentando el riesgo en 3,2 veces en los hombres y 8 veces en las mulheres<sup>18</sup>.</p>
      <p>La depresi&#243;n no ha sido analizada sistem&#225;ticamente en los pacientes con IC, pero, cuando fue investigada, se constata que es relativamente frecuente entre ellos<sup>6-13</sup>. En pacientes sin IC, cuadros de depresi&#243;n mayor son descriptos entre 14,0%-26,0% de los individuos, pero, en los portadores de IC, la incidencia aumenta para la franja de 24,0%-85,0% de los pacientes<sup>4</sup>. Su prevalencia aumenta con la edad, pero n&#237;tidamente es agravada por la presencia de IC. La incidencia de depresi&#243;n no s&#243;lo aumenta con la presencia de IC como guarda relaci&#243;n con su gravedad, siendo tanto m&#225;s frecuente cuanto m&#225;s sintom&#225;tica es la IC<sup>11,12,19</sup>. De esa forma, la frecuencia de cuadros depresivos es mayor en las cohortes de pacientes hospitalizados que entre los pacientes ambulatorios, probablemente reflejo de la mayor gravedad de la IC de los pacientes internados<sup>6-13,19</sup>. Se constata que la depresi&#243;n leve puede ser encontrada en la mayor&#237;a de los pacientes hospitalizados por descompensaci&#243;n card&#237;aca, alcanzando 85,0% de los pacientes. La depresi&#243;n grave es menos frecuente<sup>12</sup>.</p>
      <p>La depresi&#243;n no s&#243;lo es frecuente en la IC, como los pacientes con IC y depresi&#243;n tienen un riesgo de morir de dos a tres veces mayor. Los pacientes deprimidos son tambi&#233;n hospitalizados cerca de tres veces m&#225;s y la depresi&#243;n no retrocede en 1/3 de los pacientes en el primer a&#241;o de seguimiento. La depresi&#243;n aumenta los costos del tratamiento en 25,0%-40,0%, as&#237; como la tasa de hospitalizaci&#243;n, adem&#225;s de empeorar la clase funcional y perjudicar las actividades diarias<sup>12</sup>.</p>
      <p>En este estudio, procuramos evaluar la relaci&#243;n entre la IC y la depresi&#243;n en pacientes con IC avanzada. El diagn&#243;stico de depresi&#243;n es realizado a trav&#233;s de una evaluaci&#243;n psiqui&#225;trica y el test de Hamilton-D auxilia en su graduaci&#243;n, transformando la evaluaci&#243;n en n&#250;meros, lo que es &#250;til en investigaci&#243;n cient&#237;fica<sup>6,8,10,12,14,15</sup>. Con ese test, se grad&#250;a la intensidad de la depresi&#243;n, siendo que, cuanto mayor el escore, mayor la intensidad de la enfermedad. En este trabajo, empleamos el test de Hamilton-D, por su precisi&#243;n en el diagn&#243;stico de la depresi&#243;n, por la practicidad en graduarla y por haber demostrado (en varios estudios) que eval&#250;a el grado de gravedad de la depresi&#243;n.</p>
      <p>Nuestra casu&#237;stica fue compuesta por pacientes con IC avanzada. En el Hospital Auxiliar de Cotox&#243;, hay un sesgo de gravedad, pues s&#243;lo son internados pacientes que no compensaron o no mejoraron con la atenci&#243;n en la Sala de emergencias<sup>2</sup>. En esta poblaci&#243;n, 55,8% de los pacientes presentaban signos de depresi&#243;n grave o muy grave, identificados por presentar en el test de Hamilton-D, escore superior a 18.</p>
      <p>Cuando comparamos nuestros datos a los de la literatura, constatamos que la incidencia de depresi&#243;n grave entre nuestros pacientes fue m&#225;s alta que la descripta en los estudios publicados con pacientes con IC<sup>8,12,15</sup>. Las caracter&#237;sticas de nuestra poblaci&#243;n, constituida por pacientes con IC bastante acentuada, pueden ser una explicaci&#243;n para tal hallazgo, a consecuencia de la fuerte relaci&#243;n que hay entre la intensidad de la IC y la frecuencia e intensidad de la depresi&#243;n. La fisiopatolog&#237;a, con aspectos comunes entre la IC y la depresi&#243;n, puede explicar esa ocurrencia, una vez que tanto la IC como la depresi&#243;n promueven elevaci&#243;n de los niveles de las neurohormonas y de las citocinas, de tal forma que, actuando juntas, acent&#250;an las alteraciones fisiopatol&#243;gicas que, a su vez, acent&#250;an las manifestaciones cl&#237;nicas y la morbimortalidad<sup>13-17,19</sup>.</p>
      <p>Mientras tanto, fue interesante observar que, en nuestro estudio, cuando comparamos pacientes con depresi&#243;n grave (escore de Hamilton-D &gt; 18) con los sin depresi&#243;n o depresi&#243;n leve a moderada, aquellos con depresi&#243;n grave o muy grave presentaban valores m&#225;s elevados de BNP (2.582,8 &#177; 1.596,6 pg/ml vs. 1.206,6 &#177; 587,0 pg/ml; p &lt; 0,001), indicando una mayor intensidad de manifestaciones de congesti&#243;n, en contraste con los valores de la fracci&#243;n de eyecci&#243;n m&#225;s elevados (33,4 &#177; 7,2% vs. 19,5 &#177; 5,2%; p = 0,046), lo que indica menor compromiso ventricular<sup>12,13,17-19</sup>. Tales datos pueden ser considerados como una documentaci&#243;n de la referida sinergia entre la IC y la depresi&#243;n en la g&#233;nesis de las manifestaciones cl&#237;nicas de los pacientes con la enfermedad.</p>
      <p>Es importante resaltar que no hubo diferencias entre los dos grupos en cuanto al sexo, edad, anemia y funci&#243;n renal, factores estos que, reconocidamente, podr&#237;an influenciar en las manifestaciones cl&#237;nicas y en los niveles de BNP.</p>
      <p>Estos resultados difieren en algunos aspectos de los descriptos en la literatura. En el estudio HF-ACTION, se observ&#243; relaci&#243;n entre las manifestaciones cl&#237;nicas (m&#225;s acentuadas) en los pacientes con depresi&#243;n en relaci&#243;n a los no deprimidos, pero no se observ&#243; correlaci&#243;n entre medidas objetivas de la funci&#243;n card&#237;aca y la presencia de depresi&#243;n<sup>16</sup>. Mientras tanto, en nuestro estudio, constatamos una n&#237;tida relaci&#243;n entre la presencia de depresi&#243;n grave y signos objetivos de mayor intensidad de congesti&#243;n (niveles elevados de BNP). Es posible que la actuaci&#243;n sin&#233;rgica entre la IC y la depresi&#243;n, as&#237; como la presencia de un mayor n&#250;mero de casos con depresi&#243;n grave, haya acentuado las manifestaciones cl&#237;nicas a punto de volverlas diferentes estad&#237;sticamente.</p>
      <p>De cierto modo, ese menor compromiso mioc&#225;rdico y la documentaci&#243;n de mayor congesti&#243;n (BNP m&#225;s elevado) se&#241;alan la importancia que tiene la depresi&#243;n en la acentuaci&#243;n de las manifestaciones cl&#237;nicas de los pacientes deprimidos, una vez que, aun con menor compromiso card&#237;aco, presentan m&#225;s manifestaciones cl&#237;nicas. Son datos que explican porque pacientes deprimidos se hospitalizan m&#225;s que los no deprimidos.</p>
      <p>La postura de los pacientes en relaci&#243;n a la enfermedad tambi&#233;n contribuye a la g&#233;nesis de las manifestaciones. Los pacientes deprimidos adhieren menos a las orientaciones no farmacol&#243;gicas (sal y restricci&#243;n h&#237;drica) como tambi&#233;n a la obediencia al tratamiento medicamentoso<sup>15,16</sup>. La no adherencia al tratamiento es un factor descripto cada vez m&#225;s como asociado a la peor evoluci&#243;n<sup>20-23</sup>.</p>
      <p>El conjunto de datos indica fuertemente que la IC acent&#250;a o provoca la depresi&#243;n, pero lo inverso tambi&#233;n es verdadero. May et al<sup>9</sup>, estudiando 13.708 pacientes con enfermedad coronaria sin IC o depresi&#243;n, pudieron observar en el seguimiento que la IC surgi&#243; en 3,6% de los pacientes sin depresi&#243;n y en 16,4% de los deprimidos<sup>9</sup>. La depresi&#243;n fue asociada a riesgo <sup>1,5</sup> veces mayor de que el paciente presente IC en relaci&#243;n al no deprimido<sup>9</sup>.</p>
      <p>En nuestro estudio, pudimos tambi&#233;n documentar la IC como causa de depresi&#243;n. Cuando analizamos los valores de BNP y su relaci&#243;n con la incidencia de depresi&#243;n grave, pudimos constatar una fuerte relaci&#243;n entre los niveles m&#225;s elevados del BNP con una mayor incidencia de cuadros de depresi&#243;n grave o muy grave. A trav&#233;s de la curva ROC, identificamos valores encima de 1.100 pg/ml del BNP como el relacionado a la mayor prevalencia de cuadros depresivos, con 12,0 veces m&#225;s chance de que esos pacientes con IC desarrollen depresi&#243;n grave que aquellos con niveles m&#225;s bajos de BNP (<xref ref-type="fig" rid="f1-body3">Figura 1</xref>).</p>
      <fig id="f1-body3">
        <graphic xlink:href="1678-4170-abc-95-06-0732-00125-gf01-es.jpg"/></fig>
      <p>Considerando que la depresi&#243;n acent&#250;a las manifestaciones cl&#237;nicas y empeora la evoluci&#243;n de los pacientes con IC, debemos los cl&#237;nicos darle m&#225;s atenci&#243;n, no dejando de verificar si el portador de IC la presenta. La importancia de tal conducta viene creciendo, una vez que hay estudios documentando que, trat&#225;ndose la depresi&#243;n, se promueve una mejora en los s&#237;ntomas y en la calidad de vida de los pacientes. Algunos estudios tambi&#233;n documentaron que tratar la depresi&#243;n con antidepresivos puede reducir la morbimortalidad de los portadores de IC<sup>21,24</sup>.</p>
      <p>La posibilidad de modificar la historia natural de la enfermedad con el tratamiento de la depresi&#243;n merece atenci&#243;n. En esta casu&#237;stica de pacientes con IC avanzada, la mortalidad hospitalaria fue alta (27,9%), siendo que, en los pacientes con depresi&#243;n grave o muy grave, fue 2,38 veces mayor que en los con depresi&#243;n leve o moderada (37,5% vs. 15,7%; p = 0,115). A pesar de la diferencia de mortalidad, esta no fue significativa. Esos resultados deben ser valorizados con cuidado en consecuencia del tama&#241;o de la casu&#237;stica, pero son concordantes con lo que la literatura describe en cuanto a peor evoluci&#243;n de los pacientes con depresi&#243;n<sup>25</sup>.</p>
      <p>Los resultados de nuestro estudio demostraron que los cuadros depresivos graves son frecuentes entre los pacientes con IC avanzada y que su presencia acent&#250;a las manifestaciones de la descompensaci&#243;n card&#237;aca y su gravedad. El estudio mostr&#243; una relaci&#243;n de la depresi&#243;n con mayor estimulaci&#243;n neurohormonal en la IC evaluada por el BNP, con la depresi&#243;n acentuando la estimulaci&#243;n neurohormonal y la IC agravando la depresi&#243;n.</p>
      <p>Concluimos que, en la IC avanzada, la prevalencia de depresi&#243;n es alta, que los pacientes con depresi&#243;n presentan niveles m&#225;s elevados de BNP que los no deprimidos, y que, cuanto m&#225;s descompensado est&#225; el paciente, mayor es la chance de presentar depresi&#243;n grave o muy grave. Esos resultados frente a la peque&#241;a casu&#237;stica estudiada deben ser considerados como preliminares.</p>
      <p>La investigaci&#243;n de la presencia de depresi&#243;n viene siendo descuidada entre los pacientes con IC, actitud que precisa ser modificada, pues la identificaci&#243;n y el tratamiento de la depresi&#243;n pueden mejorar la calidad de vida y la evoluci&#243;n de los portadores de IC.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiamiento</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiamiento externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>No hay vinculaci&#243;n de este estudio a programas de postgrado.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
</article>
